CClinicalTrials.gg
Sign In
Status unknownNCT01994681Updated Dec 5, 2013

Testing Spectrosense EVA System for Detection of Pancreatic Cancer by Analyzing Volatile Organic Compounds (VOCs) in Exhaled Air

An observational study in Pancreatic Cancer, sponsored by Rauscher, Gregory E., M.D. PA. Status unknown at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-12-05.

Sponsored by Rauscher, Gregory E., M.D. PA · Observational

The sponsor has not verified this record recently (last verified Dec 2013), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
100
Ages
18 Years and older
Sex
All
01

Study summary

Volatile Organic Compounds (VOC) in human breath are captured and analyzed by the Spectrosense EVA system, which is combination of a gas chromatography (GC) and software algorithm. The objective is to obtain a set or sets of VOC bio-markers that will provide the best discrimination between Pancreatic Cancer sick population and healthy population. The gold standard for identifying sick/healthy population is biopsy proven Pancreatic cancer.

02

Conditions studied

  • Pancreatic Cancer
03

In context

Pancreatic Neoplasms

3,235 studies on the registry are indexed under Pancreatic Neoplasms; 899 are open to participants now.

This study's planned enrollment of 100 is below the median of 200 across 620 observational studies indexed under Pancreatic Neoplasms.

Browse Pancreatic Neoplasms studies →

Lead sponsor

Rauscher, Gregory E., M.D. PA is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with pancreatic cancer, biopsy confirmed, before treatment, ages above 18. vs. Healthy subjects without pancreatic cancer.

Eligibility criteria

Pancreatic cancer Group

Inclusion Criteria:

  • Age from 18 years old
  • Pancreatic cancer positive biopsy
  • Before any treatment
  • Signed Informed Patient Consent

Exclusion Criteria:

  • Age under 18 years old
  • Neoadjovant treatment
  • Post surgery for Pancreatic cancer
  • A history of any other cancer type, except skin cancer that is not melanoma

Healthy Group

Inclusion Criteria:

  • Healthy patients
  • No history of Pancreatic cancer
  • Signed Informed Patient Consent

Exclusion Criteria:

  • History of Pancreatic cancer
  • Pancreatic cancer background in the family
  • A history of any other cancer type, except skin cancer that is not melanoma
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Pancreatic Cancer
  • Healthy
06

What researchers measure

Primary outcomes

  1. Obtaining a set or sets of VOC bio-markers that will provide the best discrimination between Pancreatic Cancer sick population and healthy population.

    An optimization algorithm will select VOCs that will provide maximal sensitivity and specificity.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 5, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01994681
Lead sponsor
Rauscher, Gregory E., M.D. PA
Collaborators
Spectrosense Ltd.
Responsible party
Sponsor
First posted
Nov 26, 2013
Start date
Oct 2013
Primary completion
Oct 2014 (estimated)
Last update
Dec 5, 2013

Study contacts

Kevin Barga
Contact
kbarga@hackensackumc.org
(551)996-8017
Martin Gutierrez, MD
principal investigator · Hackensack Meridian Health
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Pancreatic Neoplasms→

Other studies from this sponsor

Rauscher, Gregory E., M.D. PA

Start the discussion